Clinical trials: Allogenic Disease
Bone Marrow Failure Syndromes
Comparison of Cy-Atg Vs Cy-Flu-Atg for the Conditioning Therapy in Allo-HCT
Randomized comparison of cyclophosphamide versus reduced-dose cyclophosphamide plus fludarabine in addition to anti-thymocyte globulin for the conditioning therapy in allogeneic hematopoietic cell transplantation for bone marrow…
- Trial name
- CyFluCyATG (NCT00774527)
- Testing
- Cyclophosphamide-fludarabine-anti thymocyte globulin
- Where
- South Korea
- Volunteers
- 82 people
- Sponsor
- Cooperative Study Group A for Hematology
Hematologic Malignancies, Relapse
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
The investigators hypothesize that adding carfilzomib to standard conditioning regimen for allo-HCT for advanced or high-risk hematologic malignancies will decrease post-transplant relapse and treatment-related mortality by…
- Conditions
- Hematologic Malignancies, Relapse, Graft-Versus-Host Disease
- Trial name
- NCT02145403
- Testing
- Carfilzomib, Tacrolimus
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Michigan Rogel Cancer Center
Hodgkins Lymphoma
Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma
The investigators intend to utilize reduced intensity conditioning and allogeneic stem cell transplant from EBV positive HLA matched sibling or unrelated adult donor combined with post AlloSCT allogeneic donor derived LMP…
- Trial name
- NCT01636388
- Testing
- allogeneic donor derived LMP specific cytotoxic T-lymphocyte
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- New York Medical College
Interstitial Lung Disease, Connective Tissue Diseases
Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)
Researchers are trying to find out more about the safety of a new treatment, Allogeneic (coming from a healthy donor) Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs) which is still experimental, for Interstitial Lung…
- Trial name
- NCT03929120
- Testing
- Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mayo Clinic
Immune Mediated Anemia, Immune Mediated Thrombocytopenia
Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias
Background: People who have a blood stem cell transplant can sometimes develop cytopenia. This means that their levels of one or more types of blood cell, such as the red cells or platelets, are lower than they should be.
- Conditions
- Immune Mediated Anemia, Immune Mediated Thrombocytopenia, Chronic GVHD
- Trial name
- NCT05509582
- Testing
- fostamatinib
- Where
- United States
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Leukemia, Myelodysplastic Syndromes
Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome
RATIONALE: Colony-stimulating factors, such as sargramostim, may increase the number of immune cells found in bone marrow or peripheral blood.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00003961
- Testing
- sargramostim
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Myelofibrosis
Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)
The only curative treatment for patients with myelofibrosis (MF) is allogeneic stem cell transplantation (SCT). Treatment with JAK2 inhibitors like pacritinib improves condition of MF patients, decreases spleen size and might…
- Trial name
- HOVON134MF (NCT03645824)
- Testing
- Pacritinib
- Where
- 12 sites in Belgium, Netherlands
- Volunteers
- 61 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Leukemia, Myeloid
γδ T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant
This is a prospective, double-arm, single-center, randomized controlled single-blind clinical study
- Conditions
- Leukemia, Myeloid, Acute
- Trial name
- NCT07123662
- Testing
- Gamma-Delta T cell injection, Standard prophylactic treatment
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd
Prostate Cancer
Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine
The purpose of this study is to evaluate clinical and laboratory safety in patients receiving 4 different doses of GVAX® Prostate Cancer Vaccine in order to determine a maximum tolerated dose.
- Trial name
- NCT00140348
- Testing
- Immunotherapy allogeneic GM-CSF secreting cellular vaccine
- Where
- 12 sites in United States
- Volunteers
- 80 people
- Sponsor
- Cell Genesys
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
This phase I clinical trial is studying the side effects and the best dose of lenalidomide after donor bone marrow transplant in treating patients with high-risk hematologic cancer.
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1
- Trial name
- NCT01254578
- Testing
- Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Limbal Stem Cell Deficiency
Allogeneic ABCB5-positive Limbal Stem Cells for Treatment of LSCD
The aim of this clinical trial is to investigate the efficacy (by monitoring neovascularization and epithelial defects) of up to four doses of the investigational medicinal product (IMP) LSC2 topically administered on the target…
- Trial name
- NCT03549299
- Testing
- LSC2
- Where
- 5 sites in United States, Germany
- Volunteers
- 16 people
- Sponsor
- RHEACELL GmbH & Co. KG
CMV Infection, Hematopoietic Stem Cell Transplantation
Immune Reconstitution to CMV After HSCT: Impact of Clinical Factors and Therapy Strategies
Cytomegalovirus (CMV) remains a significant cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT).
- Trial name
- NCT05656599
- Testing
- Letermovir
- Where
- 2 sites in China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Alzheimer Disease
Alzheimer's Disease Stem Cells Multiple Infusions
The purpose of this research study is to test the safety, possible side effects, and possible effectiveness of mesenchymal stem cell infusions when given to people with a diagnosis of mild to moderate Alzheimer's disease.
- Trial name
- NCT04040348
- Testing
- Approximately 100 million cells allogeneic hMSC
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Bernard (Barry) Baumel
Bronchiolitis Obliterans Syndrome (BOS), HSCT
Efficacy of an Anti-TSLP Monoclonal Antibody in the Management of Chronic Bronchial Disease Induced by Bronchiolitis Obliterans Syndrome in Allogeneic Hematopoietic Stem Cells Transplantation Recipients
Allogeneic hematopoietic stem cell transplantation (HSCT) is burdened with a high morbidity and mortality rates. Graft versus host disease (GVHD) is the clinical manifestation of an immune conflict.
- Conditions
- Bronchiolitis Obliterans Syndrome (BOS), HSCT, Bronchial Disease
- Trial name
- IMMUNO-BOS (NCT07771855)
- Testing
- Tezepelumab
- Where
- 6 sites in France
- Volunteers
- 36 people
- Sponsor
- Hopital Foch
Acute Lung Injury, Acute Respiratory Distress Syndrome
Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Acute Lung Injury
Phase I-II Clinical Trial - Safety and efficacy of umbilical-cord-derived mesenchymal stem cell (UC-MSC) in patients with Acute Lung Injury ,open label, controlled prospective study.
- Trial name
- UCMSC-ALI (NCT02444455)
- Testing
- UCMSC group
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Leukemia, Acute Lymphoblastic, Acute Myeloid Leukemia
GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia
Several groups have demonstrated very low incidence of acute and chronic graft-versus-host disease (GVHD) with post-transplantation cyclophosphamide (PTCy) in haploidentical, unrelated and related allogeneic stem cell…
- Conditions
- Leukemia, Acute Lymphoblastic, Acute Myeloid Leukemia, Mixed-Lineage Acute Leukemias
- Trial name
- NCT02799147
- Testing
- Allogeneic stem cell transplantation, Fludarabine monophosphate, Busulfan
- Where
- Russia
- Volunteers
- 27 people
- Sponsor
- St. Petersburg State Pavlov Medical University
B2 Thymoma, Thymic Carcinoma
Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
This Phase 1/2 study evaluates the safety, tolerability, and preliminary efficacy of target-selected CAR-natural killer (CAR-NK) cells in adults with relapsed or refractory B2 thymoma or thymic carcinoma.
- Trial name
- SELECT-NK-THYM (NCT07598955)
- Testing
- Cyclophosphamide, Fludarabine, EB-CAR30-NK
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
GVHD
Allogeneic Skin Grafting
The primary study objective is to evaluate local response to split-thickness skin grafts from a matched bone marrow donor to chronic GVHD-affected skin in a hematopoietic stem cell transplant patient.
- Trial name
- NCT04015947
- Testing
- CelluTome® Epidermal Harvesting System
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Minnesota
Hematological Malignancy
Phase I of Infusion of Selected Donor NK Cells After Allogeneic Stem Cell Transplantation
The goal of our study will be to determine the clinical and biological safety of infusing immuno-selected NK (Natural Killer) CD3-/CD56+ cells, early after allogeneic transplantation with colony stimulating factor (G-CSF)…
- Trial name
- DLI-NK (NCT01853358)
- Testing
- NK Cell infusion
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Institut Paoli-Calmettes
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.